Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Neoplasms 3Advanced Solid Tumor 3Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Breast Neoplasms 2Pancreatic Neoplasms 1Neuroendocrine Tumors 1Major Advanced Solid Tumors Other Than Colorectal 1Lung Neoplasms 1Leukemia 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumors 1ADVANCED SOLID TUMORS 1

Interventions

Gemcitabine 170130-nm albumin-bound paclitaxel 54Albumin-Bound Paclitaxel 42Oxaliplatin 33Fluorouracil 32pembrolizumab 30Capecitabine 30Leucovorin 28Irinotecan 28Radiotherapy 25Nivolumab 22Erlotinib Hydrochloride 21Taxes 19Cisplatin 19Bevacizumab 15Magnetic Resonance Spectroscopy 13Specimen Handling 12Radiosurgery 11Ipilimumab 11Cyclophosphamide 11Drug Therapy 10Carboplatin 10Biopsy 10Paclitaxel 9Docetaxel 9Cetuximab 9trametinib 8olaparib 8durvalumab 8Sorafenib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Pancreatic Neoplasms × PM 01183 × Clear all
NCT02210364 2016-12-14

Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).

PharmaMar

Phase 1 Completed
81 enrolled
BreastGastrointestinal

Breast Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡